Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Public ClinicalTrials.gov record NCT01951586. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This randomized phase 2 trial is studying the effect of adding denosumab to standard chemotherapy in the treatment of advanced lung cancer.
Study identification
- NCT ID
- NCT01951586
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 226 participants
Conditions and interventions
Conditions
Interventions
- Denosumab Drug
- Zoledronic acid Drug
- Placebo to Denosumab Drug
- Standard Chemotherapy Drug
- Placebo to Zoledronic Acid Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 100 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2013 (Actual)
- Primary completion
- Jul 29, 2016 (Actual)
- Completion
- Nov 28, 2017 (Actual)
- Last update posted
- Oct 25, 2021
2013 – 2017
United States locations
- U.S. sites
- 18
- U.S. states
- 13
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Goodyear | Arizona | 85338 | — |
| Research Site | Anaheim | California | 92801 | — |
| Research Site | Long Beach | California | 90813 | — |
| Research Site | Los Angeles | California | 90024 | — |
| Research Site | Los Angeles | California | 90048 | — |
| Research Site | Farmington | Connecticut | 06030-1628 | — |
| Research Site | Alexandria | Louisiana | 71301 | — |
| Research Site | Brewer | Maine | 04412 | — |
| Research Site | Westminster | Maryland | 21157 | — |
| Research Site | Fairhaven | Massachusetts | 02719 | — |
| Research Site | Detroit | Michigan | 48202 | — |
| Research Site | East Setauket | New York | 11733 | — |
| Research Site | Durham | North Carolina | 27710 | — |
| Research Site | Hickory | North Carolina | 28602 | — |
| Research Site | Winston-Salem | North Carolina | 27157 | — |
| Research Site | Bismarck | North Dakota | 58501 | — |
| Research Site | Cincinnati | Ohio | 45267 | — |
| Research Site | Nashville | Tennessee | 37203 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 56 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01951586, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 25, 2021 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01951586 live on ClinicalTrials.gov.